Healio

Tocilizumab holds firm as steroid-sparing agent in giant cell arteritis

Please provide your email address to receive an email when new articles are posted on . Tocilizumab, the one biologic therapy that has FDA approval for giant cell arteritis, has shown ongoing efficacy ...
Business Wire

Positive Phase III Results of Genentech’s Actemra (Tocilizumab) for the Treatment of Giant Cell Arteritis Published in New England Journal of Medicine

SOUTH SAN FRANCISCO, Calif.-- (BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that data from the Phase III GiACTA study, which evaluated Actemra ® ...
Pharmabiz

Roche phase III study of Actemra/RoActemra in people with GCA meets primary and key secondary endpoints

Roche announced positive results from the phase III study known as GiACTA, which evaluated Actemra/RoActemra (tocilizumab) in people with giant cell arteritis (GCA). The study met its primary and key ...
Pharmabiz

Roche announces phase III study of Actemra/RoActemra in giant cell arteritis meets its primary & secondary endpoints

Roche announced positive results from the phase III GiACTA study, which evaluated Actemra/RoActemra (tocilizumab) in people with giant cell arteritis (GCA). GiACTA met its primary and key secondary ...
Monthly Prescribing Reference

Tocilizumab Gets Priority Review for Treatment of Giant Cell Arteritis

Pexidartinib is an oral small molecule that is believed to work by inhibiting colony stimulating factor-1 receptor (CSF1R). Genentech has announced that the Food and Drug Administration (FDA) has ...